Open Beta
TREN
MetriLume
TREN

US marketsKRSA

SEC-sourced researchBeta

KRSA

Korsana Biosciences, Inc.

Company comparison ↗

Data passport

CIK
0001755237
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
5/6
Filing date
Sep 23, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 2,000,000.0000 USD; December 2025: 2,074,000.0000 USD2.1M USD0 USD0December 2024December 2025
KRSA · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20242,000,000.0000Mar 31, 2026
December 20252,074,000.0000Mar 31, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20252,074,000.0000-3,528,000.0000-3,314,000.00009,985,000.0000—Mar 31, 2026
December 20242,000,000.0000-3,057,000.0000-4,333,000.00009,575,000.0000—Mar 31, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$2.07MDecember 2025Mar 31, 202610-K
Previous period revenueRevenues$2MDecember 2024Mar 31, 202610-K
Net incomeNetIncomeLoss-$3.53MDecember 2025Mar 31, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$3.31MDecember 2025Mar 31, 202610-K
Total assetsAssets$9.99MDecember 2025Mar 31, 202610-K
Total liabilities————

New filings

Explore methodology ↗